Imminent Madrigal, Viking Trial Readouts Will Shape NASH R&D Expectations

 
• By Joseph Haas

While neither company reported new data from their ongoing trials at AASLD, the firm’s competing THRβ agonists are viewed as leading lights in the non-alcoholic steatohepatitis competition.

Close competition
Madrigal leads but Viking may be a close competitor in the NASH R&D race • Source: Shutterstock

More from Strategy

More from Business